TRIAL SUCCESS

Orasis and Aspen file BESKA for presbyopia in Australia on approved Phase 3 data

The NDA leans on NEAR-1 and NEAR-2 results already behind BESKA's U.S. approval, making replication of that Day 8 near-vision gain the bar for Australian regulators, not a new efficacy question.

By AppliedXLJuly 15, 2026Trial NCT04599933

Executive Summary

Orasis Pharmaceuticals and Aspen Pharmacare Australia filed for approval of an already-U.S.-approved presbyopia eye drop in a new market, leaning entirely on data that previously supported the domestic clearance.
The filing rests on two pivotal trials that both hit their primary endpoint, a same-day near-vision gain without loss of distance vision, with a low-frequency, consistent side-effect profile.
Pilocarpine-based drops sit inside a broader field of muscarinic and non-muscarinic presbyopia candidates in Phase 3, so the differentiator here is distribution reach into a second market rather than a new mechanism claim.
The event shifts the story from clinical proof, already established, to commercial and regulatory execution abroad, with the TGA's review as the next checkpoint.

The filing

Orasis Pharmaceuticals and Aspen Australia announced on July 15, 2026 that Aspen submitted a New Drug Application to Australia's Therapeutic Goods Administration (TGA, Australia's drug regulator) for BESKA, a pilocarpine 0.4% ophthalmic solution for presbyopia in adults. The submission marks the drug's first ex-U.S. regulatory filing; Aspen will handle its distribution and marketing in Australia if approved. BESKA is already marketed in the U.S. under the name Qlosi, so the Australian filing extends an approved product into a second market rather than seeking a first approval anywhere. ORASIS

The evidence behind it

The NDA is supported by the pivotal Phase 3 NEAR-1 (NCT04599933) and NEAR-2 trials, which enrolled more than 600 adults with presbyopia combined. Both trials met their Day 8 primary endpoint: a statistically significant 3-line or more gain in distance-corrected near visual acuity with no loss of 1 line or more in distance vision. NEAR-1 alone enrolled 309 patients and completed in February 2022, with the primary endpoint defined in the registry as the percentage of subjects achieving that near-vision gain one hour after the first dose without a 1-line or more loss of distance acuity. Key secondary endpoints, measured at additional timepoints on the same day, also met their bar. ORASIS+1

Safety signal

Treatment-related adverse events were reported in the single digits, led by headache at 6.8% and instillation site pain at 5.8%. Reported adverse-event counts in NEAR-1's own results disclosure show low rates in both the drug and vehicle (placebo-like control) arms, with one serious adverse event recorded in the vehicle group and none in the CSF-1 (pilocarpine) group. The safety profile is consistent with what pilocarpine, a decades-old cholinergic agent, has shown in other settings. ORASIS+1

The competitive field

Presbyopia's Phase 3 field includes several other pilocarpine-based programs, among them Eyenovia Inc.'s pilocarpine candidate in NCT04657172, alongside non-muscarinic entrants such as Ocuphire Pharma's phentolamine-based Nyxol and Corxel Pharmaceuticals' aceclidine, both also in Phase 3. Muscarinic M3 agonism itself is a validated mechanism with approved drugs outside ophthalmology, including muscarinic-targeted therapies in overactive bladder and COPD, so the pharmacology is not novel; the competitive question in presbyopia is which formulation and dosing regimen eye-care providers adopt as an alternative to reading glasses. NCT04599933+1

What the record shows operationally

NEAR-1's own registry history shows the primary completion date moved once, from April 2021 to December 2021, and the trial went several years between its 2022 completion and result posting in November 2023 before this Australian filing surfaced the data again. None of that history bears on the disclosed Day 8 outcome, which was already used to support the existing U.S. approval; it reflects the pace of registry housekeeping on a trial that had already read out. NCT04599933

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.